Screener
Vaxcyte, Inc. PCVX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Stockholders' Equity | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,314,981 and 131,058,858 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 147 | 134 |
| Additional paid-in capital | 5,478,270 | 4,838,736 |
| Accumulated other comprehensive loss | (6,834) | 1,587 |
| Accumulated deficit | (2,475,569) | (2,154,947) |
| Total stockholders' equity | 2,996,014 | 2,685,510 |
| Total liabilities and stockholders' equity | $3,348,308 | $3,002,717 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s total equity?
- Vaxcyte, Inc. (PCVX) reported total equity of $3B in Q1 2026.
- How has Vaxcyte, Inc.'s total equity changed year-over-year?
- Vaxcyte, Inc.'s total equity decreased by 6.4% year-over-year, from $3.2B to $3B.
- What is the long-term trend for Vaxcyte, Inc.'s total equity?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s total equity has grown at a 50.7% compound annual growth rate (CAGR), from $345.84M to $2.69B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Vaxcyte, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude